Pharmacy Medical News about Hepatitis C

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pegylated IFN-alpha-2a and ribavirin in the treatment of hepatitis C
Expert Review of Anti-infective Therapy, 10/09/09

Aghemo A et al. – Following the demonstration of a more potent antiviral effect in terms of sustained virological response rates in Phase III randomized trials, pegylated IFN coupled with ribavirin has become the standard of care for chronic hepatitis C. Currently, two forms of pegylated IFN exist, which differ significantly in terms of pharmacokinetics and dynamics, is whether these peculiarities translate into different efficacy rates being still being debated.

<< Previous
A comparison of linezolid with glycopeptides in severe MRSA...

Next >>
Does hygiene counseling have an impact on the rate of CMV primary...